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The diagnosis of tuberculosis remains challenging in individuals with difficulty in providing good quality sputum samples such as
children. Host biosignatures of inflammatory markers may be valuable in such cases, especially if they are based on more easily
obtainable samples such as saliva. To explore the potential of saliva as an alternative sample in tuberculosis diagnostic/biomarker
investigations, we evaluated the levels of 33 hostmarkers in saliva samples from individuals presenting with pulmonary tuberculosis
symptoms and compared them to those obtained in serum. Of the 38 individuals included in the study, tuberculosis disease was
confirmed in 11 (28.9%) by sputum culture. In both the tuberculosis cases and noncases, the levels of most markers were above the
minimum detectable limit in both sample types, but there was no consistent pattern regarding the ratio of markers in serum/saliva.
Fractalkine, IL-17, IL-6, IL-9, MIP-1𝛽, CRP, VEGF, and IL-5 levels in saliva and IL-6, IL-2, SAP, and SAA levels in serum were
significantly higher in tuberculosis patients (𝑃 < 0.05). These preliminary data indicate that there are significant differences in the
levels of host markers expressed in saliva in comparison to those expressed in serum and that inflammatorymarkers in both sample
types are potential diagnostic candidates for tuberculosis disease.
1. Introduction
Tuberculosis (TB) remains a global health problem. An esti-
mated 8.7 million new cases and 1.4 million deaths resulted
from the disease in 2011 [1]. A delay or failure in the diagnosis
of the disease results in treatment delay with consequent
increased opportunity for transmission, with potentially ten
people infected annually per untreated case [2]. The low
sensitivity of smear microscopy, the most commonly used
TB diagnostic test in resource-constrained settings, is well-
publicized [3, 4]. Mycobacterium tuberculosis (M.tb) culture
facilities are not widely available in resource-limited settings
and culture resultsmay take up to 42 days to become available
[5]. The development of the Xpert MTB/RIF test (Cepheid
Inc., CA, USA) has been the most important advance in
the field as the test yields results within 2 hours coupled
with the detection of rifampicin resistance [6]. The test has
a pooled sensitivity of 67–98% and specificity of about 98%
in adults [7]. However, limitations, including high costs and
the requirement for a stable electricity supply and short shelf
life of consumables [8], hamper the massive roll-out of the
test in resource-constrained and often high-burden settings.
Furthermore, diagnostic tests based on sputum are not
suitable in individuals who have difficulty in providing good
quality sputum samples such as children [9] and those with
extrapulmonary TB disease. Immunodiagnostic techniques
employing host biosignatures of inflammatorymarkers could
be valuable in such cases [10, 11], especially if based on more
easily obtainable samples such as saliva and developed into
rapid point-of-care tests.
Saliva is primarily secreted through the parotid, sub-
mandibular, and sublingual glands. It is composed of 98%
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water and contains other substances including electrolytes,
mucus, antibacterial compounds, and various enzymes [12].
It is abundantly produced in individuals of all age groups and
an average human produces 0.3 to 7mL of saliva per minute
and always has about 1mL in the oral cavity [12]. Collection
of saliva is simple, is noninvasive, and does not carry the
inconveniences or risks of drawing blood [13].
There has recently been an interest in exploring saliva for
potentially useful inflammatory biomarkers [13]. Diagnostic
tests based on saliva, such as theHIVoral fluid rapid tests [14],
are commercially available. Despite the large number of TB
biomarker discovery studies which are available in the litera-
ture, most of which are based on serum or, to a lesser extent,
urine [15–18] (reviewed in [19–21]), saliva, a relatively easy-
to-obtain and abundant sample type, has not yet attracted
much interest in the field. In the present study, we assessed the
levels of 33 host markers in saliva of individuals presenting
with symptoms suggestive of pulmonary TB and compared
them to the levels detected in serum. We show that there are
large differences in the levels of markers expressed in saliva in
comparison to serum and that some of the salivary markers
may have potential in the diagnosis of TB disease.
2. Materials and Methods
2.1. Study Participants. Individuals suspected of having pul-
monary TB disease were recruited from the Fisantekraal
community in the outskirts of Cape Town, South Africa,
as part of the ongoing EDCTP-funded African European
Tuberculosis Consortium (AE-TBC) study (http://www.ae-
tbc.eu/). Recruitment of study participants began in October
2010. At the time this pilot study was conducted, 50 partici-
pants had been enrolled at the study site, and pulmonary TB
disease had been confirmed in 11 (22%). Samples from all the
11 individuals with confirmed TB disease and 27 without TB
disease that were randomly selected from our sample bank
were included into this preliminary study. All the individuals
included in the study provided the sample pair (saliva and
serum).
All participants presented at the rural health care facility
with symptoms suggestive of pulmonary TB disease. Briefly,
participants presented with persistent cough lasting ≥2 weeks
and at least one of the following: fever, malaise, recent weight
loss, night sweats, knowledge of close contact with a TB
patient, haemoptysis, chest pain, or loss of appetite. Partici-
pants were eligible for the study if they were 18 years or older,
willing to give written informed consent for participation in
the study, including for HIV testing. Patients were excluded
from the study if they had not been residing in the study area
formore than 3months, were severely anaemic (HB< 10 g/L),
were on anti-TB treatment, had received anti-TB treatment in
the previous 90 days, orwere on quinolone or aminoglycoside
antibiotics in the past 60 days. At enrolment, a case report
form was completed for each participant before blood and
saliva samples along with other samples, including urine and
sputum as required for the main study, were collected. The
studywas approved by theHealthResearchEthicsCommittee
of the University of Stellenbosch (Reference no. N10/08/274)
and the City of Cape Town.
2.2. Sample Collection and Diagnostic Tests. Blood was col-
lected into 4mL plain BD vacutainer tubes (BD Biosciences)
and transported at ambient conditions to the laboratory. The
tubes were then centrifuged at 2500 rpm for 10 minutes after
which serum was harvested, aliquoted, and frozen (−80∘C)
until use. Saliva was collected from all participants into
salivette tubes (Sarstedt, Nu¨mbrecht, Germany), according
to the instructions of the manufacturer. Saliva samples were
then transported on ice (4∘C) to the laboratory afterwhich the
salivette tubes were centrifuged for 2minutes (1000 g) and the
saliva was harvested, aliquoted into labeled tubes, and kept at
−80∘C until analysis.
Sputum samples collected from all participants were
cultured by the MGIT method (BD Biosciences). Positive
MGIT samples were examined for AFB using the Ziehl-
Neelsen method, to check for contamination, after which
PCR experiments were performed to confirm the isolation
of M.tb complex organisms. All the individuals classified as
TB cases in this study had positive M.tb complex speciated
sputum cultures and other clinical features in keeping with
TB, including typical chest X-rays.The individuals in the “No
TB” group had negative sputum smears and cultures and had
no other signs suggestive of TB including negative chest X-
rays. None of the non-TB cases was treated for TB by the
national TB control program. All sputum and saliva samples
were processed in a BSL3 laboratory.
2.3. Luminex Multiplex Immunoassay. The levels of 33 host
markers, including interferon (IFN)-𝛾, interleukin (IL)-1𝛽,
IL-1𝛼, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70),
IL-13, IL-15, IL-17, soluble IL-2 receptor alpha (sIL-2R𝛼),
interferon inducible protein (IP)-10, tumor necrosis factor
(TNF)-𝛼, fractalkine, granulocytemonocyte colony stimulat-
ing factor (GM-CSF), epidermal growth factor (EGF), mono-
cyte chemotactic protein (MCP)-1, macrophage inflamma-
tory protein (MIP)-1𝛽, soluble CD40 ligand (sCD40L), trans-
forming growth factor (TGF)-𝛼, vascular endothelial growth
factor (VEGF), granulocyte colony stimulating factor (G-
CSF), CXCL1(GRO), C-reactive protein (CRP), serum amy-
loid protein A (SAA), serum amyloid protein P (SAP), matrix
metalloproteinase (MMP)-2, and MMP-9, were evaluated in
serumand saliva samples fromall study participants.Thiswas
done using customized Milliplex kits (Merck Millipore, St.
Charles, Missouri, USA) on the Bio-Plex platform (Bio-Rad
Laboratories, Hercules, CA, USA). All samples were analyzed
undiluted (with the exception of the samples for MMP-2,
MMP-9, CRP, SAA, and SAP) and in a blinded manner,
according to the instructions of the manufacturer (Merck
Millipore). Samples for MMP-2 and MMP-9 were predi-
luted 1 : 100 and those for CRP, SAA, and SAP were predi-
luted 1 : 8000, following optimization experiments (done on
serum). Serum and saliva samples from the same individual
were evaluated on the same plate. The levels of all analytes
in the quality control reagents were within the expected
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Figure 1: Levels of host markers detected in saliva and serum samples from all study participants (𝑛 = 38). The level of each host marker
detected in saliva was mapped to the level obtained in the serum sample from the same study participant. Representative plots for markers
more abundantly expressed in saliva are shown.
ranges.The Bio-PlexManager Software 6.0 was used for bead
acquisition and analysis of median fluorescence intensity.
2.4. Statistical Analysis. Differences in analyte levels between
the TB patients and participants without TB disease or
between the marker levels detected in saliva and serum
levels were evaluated by the Mann-Whitney 𝑈 test for
nonparametric data analysis. The diagnostic accuracy of the
markers was investigated by receiver operator characteristics
(ROC) curve analysis. Optimal cut-off values and associated
sensitivity and specificity were selected based on the highest
likelihood ratio. The predictive abilities of combinations of
analytes were estimated by performing best subsets general
discriminant analysis (GDA), with leave-one-out cross vali-
dation. Nonnormally distributed data were log-transformed
prior to the GDA procedure. Differences between groups
were considered significant if 𝑃 values were <0.05. Data were
analyzed using GraphPad Prism, version 5.00 (GraphPad
Software, San Diego, California, USA) and STATISTICA
(StatSoft, Ohio, USA).
3. Results
Of the 38 participants included in this study, 27 (71%) were
females. The mean age of all study participants was 38.0 ±
10.2. Of the 28 study participants with available Quantiferon
In-Tube results, 67.9% were positive using the manufacturer’s
recommended cut-off (≥0.35 IU/mL). Eight (21%) of the
study participants were HIV infected (Table 1).
3.1. Host Markers Detected in Saliva versus Serum. We evalu-
ated the levels of hostmarkers above theminimumdetectable
concentration (MDC; obtained from the manufacturer’s
package insert), in saliva and serum, and then compared the
levels of the markers detected in saliva to those obtained in
Table 1: Demographic and clinical characteristics of study partici-
pants.
All TB cases Non-TB case
Number of
participants 38 11 27
Mean age
(years) ± SD 38.0 ± 10.2 43.4 ± 8.7 35.9 ± 10.1
Males/females 11/27 3/8 8/19
HIV positive 𝑛 (%) 8 (21.0) 2 (18.2) 6 (22.2)
Quantiferon Positive
𝑛/number done 19/28 5/6 14/22
serum. The levels of five of the 33 markers evaluated (MMP-
9, IP-10, MIP-1𝛽, MCP-1, and sCD40L) were higher than the
MDC, in both the serumand saliva samples fromall (100%) of
the study participants. The levels of six (IL-8, G-CSF, TGF-𝛼,
EGF, VEGF, and GRO) were above the MDC in both sample
types in at least 90% of the study participants, while the levels
of IL-4 and IL-9 were undetectable or only barely detectable
in both sample types, in all study participants (Table 2).
There were, on average, 6-fold higher levels of IFN-𝛾,
IL-1𝛼, IL-12(p70), IL-13, IL-15, IL-17, fractalkine, GM-CSF,
and EGF in saliva samples from all study participants in
comparison to serum levels. The levels of IL-1𝛽, IL-2, IL-
5, IL-6, IL-7, IL-8, IL-10, G-CSF, VEGF, and MMP-9 were
also significantly higher in saliva (Table 2, Figure 1). There
were, on average, 4-fold higher levels of IP-10, MIP-1𝛽, GRO,
and CRP detected in serum samples of all study participants
in comparison to the salivary levels. SAA, SAP, sIL-2R𝛼,
sCD40L, MCP-1, and MMP-2 levels were also significantly
higher in serum (Table 2, Figure 2). When the marker levels
obtained in serum were compared to the levels obtained in
saliva only in the TB or non-TB cases, the same expression
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Table 2: Proportion of study participants with host markers above the minimum detectable concentration (MDC) and differences between
saliva and serum.
Marker MDC (pg/mL) Saliva Serum 𝑃 value
% >MDC Median (IQR) % >MDC Median (IQR)
(A) Host markers more abundantly expressed in saliva
IL-1𝛼 1.5 100.0 4618.9 (1956.3–10000.0) 21.0 0.0 (0.0-0.0) <0.0001
IL-1𝛽 0.7 95.0 24.6 (12.23–54.7) 18.0 0.0 (0.0–0.2) <0.0001
IL-2 0.4 97.0 6.5 (2.3–14.4) 32.0 0.0 (0.0–0.6) <0.0001
IL-5 0.1 32.0 0.0 (0.0–1.1) 0.0 0.0 (0.0-0.0) <0.0001
IL-7 1.0 45.0 0.0 (0.0–19.0) 16.0 0.0 (0.0-0.0) <0.0001
IL-8 0.3 100.0 145.2 (78.6–237.3) 97.0 13.6 (6.2–27.7) <0.0001
IL-10 0.3 39.5 0.0 (0.0–16.8) 2.6 0.0 (0.0-0.0) <0.0001
IL-12p70 0.9 89.0 9.8 (3.7–16.9) 16.0 0.0 (0.0–0.3) <0.0001
IL-13 0.3 92.0 20.7 (11.4–34.1) 0.0 0.0 (0.0-0.0) <0.0001
IL-15 0.6 45.0 0.0 (0.0–8.4) 5.0 0.0 (0.0-0.0) <0.0001
IL-17 0.4 97.0 13.0 (8.6–18.9) 16.0 0.0 (0.0-0.0) <0.0001
IFN-𝛾 0.4 82.0 4.1 (0.6–10.4) 42.0 0.0 (0.0–5.0) <0.0001
G-CSF 3.9 100.0 1348.0 (842.0–2263.2) 97.0 90.7 (45.3–114.4) <0.0001
GM-CSF 2.3 100.0 100.5 (65.3–137.9) 8.0 0.0 (0.0-0.0) <0.0001
TGF-𝛼 1.4 100.0 9.5 (6.7–16.6) 92.0 6.9 (3.2–20.8) 0.08
EGF 5.3 100.0 5717.0 (3991.9–7964.4) 97.0 98.6 (45.5–185.1) <0.0001
VEGF 10.1 100.0 618.2 (457.3–802.6) 95.0 303.5 (145.7–493.2) <0.0001
Fractalkine 7.6 97.0 451.8 (137.9–699.9) 10.0 0.0 (0.0-0.0) <0.0001
MMP-9 1.0 100.0 164631.4 (105484.3–348292.9) 100.0 2673.0 (1795.9–3951.6) <0.0001
(B) Markers more abundantly expressed in serum
sIL-2R𝛼 7.5 8.0 0.0 (0.0-0.0) 29.0 0.0 (0.0–10.4) 0.01
GRO 11.4 97.0 132.5 (74.1–204.0) 100.0 1209.1 (856.0–2099.6) <0.0001
IP-10 1.3 100.0 102.6 (67.4–213.3) 100.0 408.0 (307.4–710.0) <0.0001
MIP-1𝛽 3.2 100.0 12.0 (8.4–17.0) 100.0 47.7 (22.2–81.3) <0.0001
MCP-1 1.2 100.0 124.5 (29.5–204.0) 100.0 473.4 (314.3–644.6) <0.0001
CRP 0.0012∗ 71.0 88.2 (0.0–232.0) 100.0 27668.5 (9213.7–127253.2) <0.0001
SAA 0.21∗ 50.0 119.5 (0.0–848.8) 97.0 11408.9 (2519.1–95050.4) <0.0001
SAP 0.055∗ 21.0 0.0 (0.0-0.0) 100.0 46954.9 (37567.1–60894.8) <0.0001
MMP-2 48 13.0 0.0 (0.0-0.0) 100.0 1148.8 (971.1–1333.0) <0.0001
sCD40L 5.2 100.0 353.8 (166.9–779.2) 100.0 ∗705911 (307862–1039000) <0.0001
(C) No difference in expression levels between serum and saliva
IL-4 0.6 0.0 0.0 (0.0-0.0) 0.0 0.0 (0.0-0.0) —
IL-6 0.4 45.0 0.0 (0.0–37.3) 32.0 0.0 (0.0–11.5) 0.12
IL-9 1.1 15.8 0.0 (0.0-0.0) 5.3 0.0 (0.0-0.0) 0.14
TNF-𝛼 0.2 87.0 10.6 (6.9–20.6) 95.0 11.1 (6.5–13.0) 0.23
Median levels of biomarkers detected in saliva and serum samples from all study participants (𝑛 = 38) and the proportion of participants in whom eachmarker
was >MDC are shown.MDC values were obtained from the package insert of the kit used. ∗Marker levels are in pg/mL except for CRP, SAA, and SAP (ng/mL).
IQR: inter-quartile range.
pattern (obtained for all study participants, that is, the two
groups together) was observed (data not shown).
3.2. Accuracy of Markers Detected in Saliva in the Diagnosis of
TB Disease. When the levels of markers detected in saliva of
TB cases were compared to the levels obtained in the saliva of
the noncases, 8 of the 33 markers (IL-6, CRP, IL-9, IL-5, MIP-
1𝛽, fractalkine, IL-17, and VEGF) were significantly different,
or showed trends for differences between the two groups
(Table 3). With the exception of VEGF, the median levels of
all 8 markers were higher in the TB cases (Table 3). When the
diagnostic accuracy of the markers was evaluated by receiver
operator characteristics (ROC) curve analysis, IL-6, CRP,
MIP-1𝛽, and fractalkine showed potential in the diagnosis
of TB disease (AUC ≥ 0.70) (Table 3). Although none of the
markers diagnosed TB disease with sensitivity ≥64% at the
cut-off level corresponding to the highest likelihood ratio,
salivary CRP, MIP-1𝛽, and fractalkine levels ascertained TB
disease with specificity ≥93% (Table 3, Figure 3).
When the data obtained from saliva were fitted into gen-
eral discriminant analysis (GDA)models, optimal prediction
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Figure 2: Levels of host markers detected in saliva and serum samples from all study participants (𝑛 = 38). The level of each host marker
detected in Saliva was mapped to the level obtained in the serum sample from the same study participant. Representative plots for markers
more abundantly expressed in serum are shown.
of TB or no TB disease was achieved when markers were
used in combinations of five. A combination of IL-5, IL-6,
IL-15, TNF-𝛼, and CRP accurately predicted 81.8% of the TB
cases and 81.4% of the noncases after leave-one-out cross
validation. The most frequently occurring analytes in the 20
most accurate discriminatory models included IL-5, IL-6, IL-
15, CRP, TNF-𝛼, and GRO (Figure 4).
3.3. Accuracy of Markers Detected in Serum in the Diagnosis
of TB Disease. When serum marker levels obtained in TB
cases were compared to the levels obtained in the noncases,
significant differences were obtained for four markers (IL-6,
IL-2, SAP, and SAA). The levels of IL-6, IL-2, and SAP were
significantly higher in the TB cases (𝑃 ≤ 0.03) while SAA
levels were higher in the noncases (Table 4).
When the diagnostic accuracy of the markers detected in
serum was investigated by ROC curve analysis, the AUC for
all four markers that showed significant differences (IL-2, IL-
6, SAP, and SAP) was ≥0.70 (Table 4, Figure 4). Of the four
markers, only SAP ascertained TB disease with sensitivity up
to 55%, but specificity was between 85.2% and 96.3% for all
four markers at cut-off levels corresponding to the highest
likelihood ratio (Table 4, Figure 5).
When the data obtained from serum samples was fitted
into GDA models, the prediction accuracy of the 5-marker
serum analytes tended to be poorer than that obtained for the
models generated on saliva data. A combination of IL-6, IL-
12p70, G-CSF, MMP-9, andMIP-1𝛽 could only predict 54.6%
of the TB cases and 81.5% of the noncases after leave-one-
out cross validation.When the GDA procedure was repeated,
with the data obtained from serum and saliva combined,
the prediction accuracy of the models increased. IL-5 and
IL-6 levels in saliva + G-CSF, IL-12p70, and IL-6 in serum
accurately classified all (100%) of the TB cases and 85.2%
of the noncases after leave-one-out cross validation. The
most frequently occurring analytes in the predictive models
comprising of markers derived from both serum and saliva
included serum IL-6, G-CSF, and IL-12p70 and salivary IL-5,
IL-6, and IL-7 (Figure 4).
4. Discussion
We evaluated the levels of 33 host immunological biomarkers
in saliva and serum samples from individuals suspected of
having pulmonary TB disease. The main finding of our study
was the dissimilar expression of host markers that were
detected in both sample types, with up to 6-fold higher
levels of some markers expressed in saliva. We have therefore
shown that saliva, a relatively easy-to-obtain sample type,
may be a very valuable sample in TB biomarker discovery
investigations. Interestingly, some of the markers detected in
saliva including IL-6, CRP, MIP-1𝛽, and fractalkine showed
potential in the diagnosis of TB disease.
All the markers evaluated in this study are inflammatory
markers including cytokines, chemokines, growth factors,
acute phase proteins, andmatrixmetalloproteinases that have
been widely investigated and shown to play diverse roles in
the pathogenesis of different diseases including TB. Of note,
the levels of IL-5, IL-6, IL-9, IL-17, MIP-1𝛽, fractalkine, CRP,
and VEGF in saliva and those of IL-2, IL-6, SAA, and SAP
in serum were significantly different or showed trends (𝑃 ≤
0.009) between the TB cases and individuals without active
TB disease. IL-2, IL-6, MIP-1𝛽, fractalkine, CRP, SAA, and
SAP in serum or saliva showed potential as TB diagnostic
candidates, as ascertained by area under the ROC curve.
IL-2 (reviewed in [22]) is an important immunomodula-
tory cytokine that is produced bymultiple cell types including
activated T-cells, dendritic cells, and NK cells and is crucial
both for the immune responses against many infectious
diseases and for the maintenance of tolerance [22]. IL-2
has been extensively investigated especially in T-cell based
studies and has shown potential as a diagnostic marker for
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Table 3: Utility of host markers detected in saliva in the diagnosis of TB disease.
Marker TB disease No TB disease 𝑃 value AUC(95% CI)
Cut-
off
value
Sensitivity %
(95% CI)
Specificity %
(95% CI)
IL-6 37.3 (0.0–52.2) 0.0 (0.0–13.2) 0.019 0.72 (0.54–0.91) >25.8 63.6 (30.8–89.0) 81.5 (61.9–93.7)
CRP 246.5 (22.0–353.9) 45.9 (0.0–122.0) 0.024 0.74 (0.53–0.94) >271.7 45.5 (16.8–76.6) 92.6 (75.7–99.0)
IL-9 0.0 (0.0–11.0) 0.0 (0.0-0.0) 0.027 0.65 (0.44–0.86) >10.3 27.3 (6.0–60.9) 96.3 (81.0–99.9)
IL-5 0.9 (0.0–9.2) 0.0 (0.0-0.0) 0.033 0.68 (0.48–0.88) >7.8 27.3 (6.0–61.0) 96.3 (81.0–99.9)
MIP-1𝛽 17.0 (11.3–22.2) 11.3 (8.4–15.6) 0.039 0.72 (0.54–0.90) >18.7 45.5 (16.8–76.6) 92.6 (75.7–99.1)
Fractalkine 772.9 (225.8–1148.3) 338.2 (104.3–565.5) 0.041 0.72 (0.52–0.91) >912.2 36.4 (10.9–69.2) 96.3 (81.0–99.9)
IL-17 18.9 (7.6–37.0) 12.6 (8.6–16.6) 0.085 0.68 (0.46–0.90) >29.0 45.5 (16.8–76.6) 96.3 (81.0–99.9)
VEGF 457.3 (307.7–754.9) 680.0 (512.4–802.6) 0.085 0.68 (0.47–0.90) <370.5 45.5 (16.8–76.6) 92.6 (75.7–99.1)
Median levels and interquartile ranges (in parenthesis) of the markers and abilities to discriminate between pulmonary TB cases (𝑛 = 11) and individuals
without active TB (𝑛 = 27) are shown. Only markers for which Mann-Whitney 𝑈 𝑃 values were ≤0.09 are shown. AUC: area under the receiver operator
characteristics (ROC) curve; 95% CI: 95% confidence interval. The cut-off values are for sensitivity and specificity for TB disease and were selected based on
the highest likelihood ratio. Marker levels are in pg/mL except for CRP (ng/mL).
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Figure 3: Levels of markers detected in the saliva samples of pulmonary TB cases and individuals without TB disease and receiver operator
characteristics (ROC) plots showing the accuracy of these markers in the diagnosis of TB disease. Error bars in the scatter-dot plots indicate
the median analyte levels. Only markers for which the area under the ROC curve (AUC) was ≥0.70 are shown.
TB disease [23, 24]. IL-6 (reviewed in [25]) is a pleiotropic
cytokine and has diverse effects on the regulation of immune
responses, inflammation, oncogenesis, and haematopoiesis
amongst others and is widely known as an inducer of the
acute phase response. IL-6 has previously been shown to be
produced in higher levels in TB patients [26, 27] and was the
only marker that showed potential as a diagnostic candidate
in both serum and saliva samples in this study. Fractalkine
is induced in endothelial cells and antigen presenting cells in
the presence of various TH1 favoring signals including IFN-
𝛾, CD40L, and TNF-𝛼 and is inhibited in the presence of
IL-4/IL-13 [28]. MIP-1𝛽 is mainly produced by macrophages,
dendritic cells, NK cells, and T-cells [29, 30]. It has been
investigated as a diagnostic candidate in T cell based studies,
but the potential shown in some adult studies [31, 32] was
not confirmed in children [33]. In this study, MIP-1𝛽 showed
potential in the diagnosis of TB disease in saliva but not in
serum. CRP, SAA, and SAP are acute phase proteins and are
secreted during the acute phase of an inflammation where
they function as opsonins or in the recruitment of cells
to inflammatory sites [34]. These nonspecific inflammatory
markers are known to be predominantly produced by the
liver and have been investigated in many diseases [34, 35].
CRP has previously been suggested as a marker for both
the diagnosis [35, 36] and extent of disease in TB [37, 38].
SAA has been suggested as a more sensitive indicator of
inflammation than CRP [39], and serum levels increase by
1000-fold in response to infection [40]. Like SAA, SAP is
structurally similar to CRP (51% sequence homology) and
SAP levels have been proved to be high in TB in murine
models, whereas purified mouse SAP inhibited the growth
of M.tb in alveolar macrophages [41]. Our observations that
these markers possess diagnostic potential for TB disease are
in line with these previous findings.
One of the most noticeable observations of our study was
the marked differences in the levels of the markers detected
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Table 4: Utility of host markers detected in serum in the diagnosis of TB disease.
Marker TB cases Non-TB cases 𝑃 value AUC(95% CI)
Cut-off
value
Sensitivity %
(95% CI)
Specificity %
(95% CI)
IL-6 11.5 (0.0–28.1) 0.0 (0.0-0.0) 0.01 0.73 (0.54–0.92) >27.54 27.3 (6.0–61.0) 96.3 (81.0–99.9)
IL-2 0.6 (0.0–1.3) 0.0 (0.0-0.0) 0.01 0.73 (0.53–0.92) >0.95 45.5 (16.8–76.6) 92.6 (75.7–99.1)
SAP 60894.8 (45137.4–65623.2) 42251.4 (36985.9–53804.8) 0.03 0.72 (0.54–0.90) >58914 54.6 (23.4–83.3) 85.2 (66.3–95.8)
SAA 239.1 (0.0–848.8) 6133.8 (2012.1–40070.2) 0.05 0.70 (0.52–0.88) >941894 18.2 (2.3–51.8) 96.3 (81.0–99.9)
Median levels (pg/mL) and interquartile ranges (in parenthesis) of the markers and abilities to discriminate between pulmonary TB cases (𝑛 = 11) and
individuals without active TB (𝑛 = 27) are shown. Only markers for which Mann-Whitney 𝑈 𝑃 values were ≤0.09 are shown. AUC: area under the receiver
operator characteristics (ROC) curve; 95% CI: 95% confidence interval. The cut-off values are for sensitivity and specificity for TB disease and were selected
based on the highest likelihood ratio. Marker levels are in pg/mL except for SAA and SAP (ng/mL).
22
20
18
16
14
12
10
8
6
4
2
0
N
um
be
r o
f t
im
es
 en
te
re
d
IL
-5
 (s
al
iv
a)
IL
-6
 (s
al
iv
a)
lo
g 
CR
P 
(s
al
iv
a)
IL
-1
5 
(s
al
iv
a)
lo
g-
TN
F-
𝛼
lo
g 
G
RO
 (s
al
iv
a)
lo
g 
IL
-1
𝛼
(s
al
iv
a)
lo
g 
IF
N
-𝛾
(s
al
iv
a)
lo
g 
SA
P 
(s
al
iv
a)
lo
g 
EG
F 
(s
al
iv
a)
lo
g 
M
CP
-1
 (s
al
iv
a)
lo
g 
M
M
P-
9 
(s
al
iv
a)
lo
g 
IP
-1
0 
(s
al
iv
a)
lo
g 
IL
-1
𝛽
(s
al
iv
a)
lo
g 
IL
-8
 (s
al
iv
a)
IL
-1
7 
(s
al
iv
a)
(s
al
iv
a)
(a)
22
20
18
16
14
12
10
8
6
4
2
0
N
um
be
r o
f t
im
es
 en
te
re
d
IL
-6
 (s
er
um
)
lo
g 
G
-C
SF
 (s
er
um
)
IL
-1
2p
70
 (s
er
um
)
IL
-5
 (s
al
iv
a)
IL
-7
 (s
al
iv
a)
IL
-6
 (s
al
iv
a)
lo
g 
IF
N
-𝛾
(s
al
iv
a)
lo
g 
sC
D
40
L 
(s
er
um
)
lo
g 
IL
-2
 (s
er
um
)
lo
g 
M
IP
-1
𝛽
(s
al
iv
a)
lo
g 
EG
F 
(s
al
iv
a)
lo
g 
IL
-1
𝛼
(s
al
iv
a)
lo
g 
SA
P 
(s
al
iv
a)
lo
g 
G
-C
SF
 (s
al
iv
a)
lo
g 
IL
-8
 (s
al
iv
a)
IL
-1
5 
(s
al
iv
a)
lo
g 
EG
F 
(s
er
um
)
lo
g 
M
IP
-1
𝛽
(s
er
um
)
lo
g 
SA
A
 (s
er
um
)
(b)
Figure 4: Frequency of analytes in the top 20GDA predictive models that most accurately classified study participants as TB disease or no
TB. The columns represent the number of times each analyte was included in the top 20 discriminatory models. (a) Frequency of analytes in
the models generated from the host markers detected in saliva, (b) frequency of analytes in models generated when the data obtained from
saliva were combined with the data obtained from serum samples.
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Figure 5: Levels of markers detected in the serum samples of pulmonary TB cases and individuals without TB disease and receiver operator
characteristics (ROC) plots showing the accuracy of these markers in the diagnosis of TB disease. Error bars in the scatter-dot plots indicate
the median analyte levels. Only markers for which the area under the ROC curve (AUC) was ≥0.70 are shown.
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in saliva and serum and that higher levels of most of the
markers were obtained in saliva. Most of the markers that
were more abundantly expressed in serum were chemokines
(IP-10, MIP-1𝛽, and MCP-1), acute phase proteins (CRP,
SAA, SAP), and sIL-2R and sCD40L, both are ligands for
molecules required for activation and differentiation of T
cells, and GRO is an angiogenesis mediator. Higher levels of
the most commonly investigated proinflammatory cytokines
and growth factors were obtained in saliva. Our observations
are in agreement with findings that the salivary gland is a
reservoir of many growth factors in rodents [42]. In humans,
EGF, basic fibroblast growth factor, insulin, and insulin-like
growth factor family members have been detected in the
salivary gland, even though their physiological role remains
unclear [42].
Although investigations on saliva in the TB biomarker
field are limited, saliva has been widely investigated in
other diseases, notably in leukaemia, oral cancer, oral lichen
planus, and periodontitis amongst others [43, 44]. US FDA
approved saliva-based commercial HIV rapid tests which
currently exist [45]. The many advantages of using saliva
as a diagnostic sample have been discussed elsewhere [44].
Our observations confirm the potential usefulness of saliva in
TB biomarker research. The high levels of the host markers
in saliva implies that these markers may be more reliably
measured even with lateral flow devices, which are usually
easy to perform and suitable even for remote settings, but
often have low limits of detection. Although diagnostic tests
based on salivary inflammatory markers may lack specificity
as the levels of these markers might also be high in other
diseases, the markers might be useful when combined with
clinical information. Such tests will be highly useful in the
TB diagnostic field, given the difficulties obtained with diag-
nosing TB disease when inadequate sputum is obtained and
when there is an inability to expectorate as obtained in young
children [9] and in extrapulmonary TB cases. All the TB cases
evaluated in this study were adults and all were diagnosed
with pulmonary TB diseases. We cannot ascertain, based on
the data presented in this study, whether these markers will
be useful in children and in those with extrapulmonary TB
disease.There is therefore a need for further investigations in
children, those with extra pulmonary TB and as those with
other lung diseases. Children and those with extrapulmonary
TB in particular would benefit the most from novel, easy-
to-perform nonsputum based diagnostic tests. Although the
use of a biosignature comprising inflammatory cytokines is
highly desirable and needed in the TB diagnostic filed, it is
important to caution that most of the markers identified in
this study (e.g., the acute phase proteins) will be elevated in
other infectious diseases. Therefore, data obtained from such
diagnostic modalities will need to be interpreted, taking into
account the clinical picture of the patient.
This study was done as a pilot for a larger, on-going study
and, as such, was limited by the small sample size and the
absence of individuals with other lung infections. However,
our observations will serve as proof-of-concept for more
research in the field given the fact that diagnostic tests based
on easily obtainable samples like saliva would revolutionize
the diagnosis of TB disease, especially if such markers are
incorporated into lateral flow devices. We did not investigate
the influence of factors such as food or drink in-take prior
to sampling on the levels of the salivary biomarkers. The
potential influence of such factors may require investigation
in further studies.
5. Conclusions
In conclusion, the data presented in this study indicates that
there are many differences in the levels of host markers
expressed in saliva in comparison to those of serum and
some of the markers detected in both sample types have
potential in the diagnosis of TB disease. Our findings indicate
that saliva might be a better alternative to serum in TB
biomarker discovery investigations. Our findings warrant
further investigation in larger studies.
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